Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.

Hypertension · 2026 · PMC13001893 · PMID 41717679

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significanceP =0.13not close (p > 0.1)

In female patients (n=91), a numerically greater reduction in MSSBP was also observed with telmisartan/amlodipine/chlorthalidone compared with telmisartan monotherapy, although the difference did not reach statistical significance (LS mean difference, −3.9 mm Hg [95% CI, −9.1 to 1.2]; P =0.13; Table S3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.